Last Price$33.90.6%
Market Cap$15.2B
(3.8%)
Industry median - 16.5%
5Y Historical average - 28.4%
(13.4%)
Industry median - 6.8%
5Y Historical average - 33.5%
(9.0%)
Industry median - (16.5%)
5Y Historical average - 396.2%
215.8%
Industry median - 9.2%
5Y Historical average - 60.3%
RPRX Growth Rating
RPRX Growth rating
4.9
RPRX Growth rating performance
RPRX Growth Metrics
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Competing with RPRX Growth
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Growth score | Revenue Growth
(5Y CAGR) | Revenue Growth
(YoY) | Revenue Growth
(FWD) | EPS Growth
(5Y CAGR) | EPS Growth
(YoY) | EPS Growth
(FWD) | FCF Growth
(5Y CAGR) | FCF Growth
(YoY) |
$15.2B | 4.9 | 4.5% | (3.8%) | 35.2% | (19.0%) | (9.0%) | 132.7% | 10.6% | 215.8% | |
$402.0B | 7.6 | 18.9% | 25.0% | 19.9% | 6.7% | (17.3%) | 23.5% | 14.5% | 0.0% | |
$125.5B | 6.8 | 21.5% | 11.5% | 6.8% | N/A | N/A | (988.1%) | N/A | N/A | |
$74.0B | 5.5 | 12.6% | 8.3% | 3.4% | 16.1% | 10.3% | 9.5% | 12.5% | (5.7%) | |
$38.1B | 6.2 | 106.9% | 127.3% | 76.7% | (9.7%) | (57.5%) | (141.9%) | N/A | (70.8%) | |
$31.3B | 5.4 | 59.2% | 23.0% | 16.9% | (23.2%) | (38.5%) | (55.3%) | (36.7%) | N/A | |
$27.1B | 6.1 | 83.9% | (54.1%) | (28.2%) | 29.6% | N/A | (182.9%) | N/A | (79.0%) | |
$14.8B | 3.8 | 14.5% | 14.8% | 9.3% | (35.1%) | (91.0%) | 3,612.9% | (18.0%) | (47.6%) | |
$14.6B | 5.7 | (100.0%) | N/A | N/A | (7.1%) | (94.8%) | 6.8% | 44.6% | 84.8% | |
$14.0B | 7.5 | 14.7% | 23.6% | 10.7% | N/A | 25.6% | 9.9% | N/A | 44.5% | |
$1,846.9M | 5.0 | 50.5% | 50.5% | 50.7% | (11.2%) | (16.6%) | (35.6%) | 2.7% | (45.5%) |
FAQ
What is the Royalty Pharma plc (RPRX) revenue growth?
The Royalty Pharma plc (RPRX) revenue growth is (3.8%), which is lower than the industry median of 16.5% and the 5-year historical average of 28.4%.
What is the Royalty Pharma plc (RPRX) operating income growth?
The Royalty Pharma plc (RPRX) operating income growth is (13.4%), compared to the industry median of 6.8% and the 5-year historical average of 33.5%.
What is the Royalty Pharma plc (RPRX) EPS (Earnings Per Share) growth?
The Royalty Pharma plc (RPRX) EPS growth is (9.0%), compared to the industry median of (16.5%) and the 5-year historical average of 396.2%.
What is the Royalty Pharma plc (RPRX) Free Cash Flow (FCF) growth?
The Royalty Pharma plc (RPRX) Free Cash Flow growth is 215.8%, compared to the industry median of 9.2% and the 5-year historical average of 60.3%.